• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sidoti's November Micro-Cap Virtual Conference

    11/8/22 3:40:00 PM ET
    $CGRN
    $DPSI
    $FGI
    $GIFI
    Industrial Machinery/Components
    Industrials
    Computer Software: Programming Data Processing
    Technology
    Get the next $CGRN alert in real time by email
    • Presentation Times and Weblinks Released for Over 35 Presenting Companies
    • Wednesday and Thursday, November 9-10, 2022

    NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 9-10, 2022. The links can also be found at www.sidoticonference.com/events .

    Sidoti & Company, LLC, Tuesday, November 8, 2022, Press release picture

    Presentation Agenda

    Wednesday, November 9th, 2022 (Day 1)

    9:15-9:45

    Bel Fuse (BELFB)

    Splash Beverage Group (SBEV)

    Generation Income Properties (GIPR)

    10:00-10:30

    *****

    Miromatrix Medical Inc. (MIRO)

    FRX Innovations (FRXI)

    10:45-11:15

    Guerrilla RF (GUER)

    CVG (CVGI)

    EzFill Holdings (EZFL)

    11:30-12:00

    CareCloud (MTBC)

    Mistras Group (MG)

    *****

    12:15-12:45

    Civeo Corporation (CVEO)

    XORTX Therapeutics, Inc. (XRTX)

    Mill City Ventures III (MCVT)

    1:00-1:30

    *****

    Blue Star Foods (BSFC)

    Argentina Lithium & Energy (PNXLF)

    1:45-2:15

    *****

    Akari Therapeutics (AKTX)

    Conifex Timber Inc. (CFF)

    2:30-3:00

    Ascent Industries Co. (ACNT)

    Transcode (RNAZ)

    Ashford Hospitality Trust (AHT)

    3:15-3:45

    Heartcore Enterprises, Inc. (HTCR)

    Electromed, Inc. (ELMD)

    *****

    4:00-4:30

    ShiftPixy, Inc. (PIXY)

    Propanc Biopharma Inc. (PPCB)

    *****

    1x1s Only

    Quanex Building Products (NX)

    Thursday, November 10th, 2022 (Day 2)

    9:15-9:45

    SmartKem (SMTK)

    TARENA International (TEDU)

    *****

    10:00-10:30

    *****

    Loop Industries (LOOP)

    *****

    10:45-11:15

    TESSCO Technologies (TESS)

    *****

    *****

    11:30-12:00

    DecisionPoint Systems (DPSI)

    *****

    Independence Contract Drilling (ICD)

    12:15-12:45

    Boardwalktech Software (BWLKF)

    HOOKIPA Pharma Inc. (HOOK)

    *****

    1:00-1:30

    SOBR Safe Inc (SOBR)

    MAIA Biotechnology, Inc. (MAIA)

    Capstone Green Energy (CGRN)

    1x1s Only

    FGI Industries (FGI) | Gulf Island Fabrication (GIFI)

    About Sidoti
    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences ( www.sidoti.com/events ) we host each year.

    CONTACT
    Sidoti Events Team
    212-453-7031
    [email protected]

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/724582/Sidotis-November-Micro-Cap-Virtual-Conference

    Get the next $CGRN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGRN
    $DPSI
    $FGI
    $GIFI

    CompanyDatePrice TargetRatingAnalyst
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Gulf Island Fabrication Inc.
    $GIFI
    3/8/2024Hold → Accumulate
    Johnson Rice
    Loop Industries Inc.
    $LOOP
    12/29/2022Buy → Neutral
    H.C. Wainwright
    HOOKIPA Pharma Inc.
    $HOOK
    12/2/2022Neutral → Underperform
    BofA Securities
    Independence Contract Drilling Inc.
    $ICD
    3/22/2022$7.00Hold → Buy
    Johnson Rice
    FGI Industries Ltd.
    $FGI
    2/23/2022$7.00Outperform
    Northland Capital Markets
    HOOKIPA Pharma Inc.
    $HOOK
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gulf Island Fab upgraded by Johnson Rice

    Johnson Rice upgraded Gulf Island Fab from Hold to Accumulate

    3/8/24 11:07:40 AM ET
    $GIFI
    Metal Fabrications
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hart Spencer bought $66,070 worth of shares (50,000 units at $1.32), increasing direct ownership by 14% to 410,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/12/25 4:33:21 PM ET
    $LOOP
    Major Chemicals
    Industrials

    Director Smith Stan bought $24,999 worth of shares (19,230 units at $1.30) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    10/2/25 4:51:47 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hart Spencer bought $33,100 worth of shares (20,000 units at $1.66), increasing direct ownership by 6% to 360,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    8/7/25 8:10:14 PM ET
    $LOOP
    Major Chemicals
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    SEC Filings

    View All

    SEC Form PREM14A filed by Gulf Island Fabrication Inc.

    PREM14A - GULF ISLAND FABRICATION INC (0001031623) (Filer)

    11/21/25 4:22:30 PM ET
    $GIFI
    Metal Fabrications
    Industrials

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    11/21/25 9:15:24 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    11/20/25 9:00:27 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

    Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Society for Immunotherapy of Cancer, held November 5-9, 2025, in National Harbor, MD. The Trials in Progress posters focus on MAIA's ongoing Phase 2 THIO-101 expansion (Part C) and Phase 3 THIO-104 clinical tri

    11/21/25 9:01:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation

    Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a presentation by CEO Vlad Vitoc, M.D. at Smart Diaspora 2025, a conference dedicated to advancing oncology research and innovation in Romania. Dr. Vitoc noted Romania as the most recent country to begin screening patients for the expansion phase of its THIO-101 Phase 2 clinical trial which evaluates ateganosine sequenced

    11/20/25 8:47:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FGI INDUSTRIES ANNOUNCES THIRD QUARTER 2025 RESULTS

    EAST HANOVER, N.J., Nov. 14, 2025 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results for the third quarter 2025. THIRD QUARTER 2025 HIGHLIGHTS(As compared to the third quarter of 2024) Total revenue of $35.8 million, -0.7% y/yGross profit of $9.5 million, +2.0% y/yGross margin of 26.5%, +70 bps y/yOperating income of $0.4 million and net loss attributable to shareholders of $1,651,000Adjusted operating income of $0.4 millionAdjusted net income of $241,000MANAGEMENT COMMENTAR

    11/14/25 4:15:00 PM ET
    $FGI
    Industrial Specialties
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hart Spencer bought $66,070 worth of shares (50,000 units at $1.32), increasing direct ownership by 14% to 410,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/12/25 4:33:21 PM ET
    $LOOP
    Major Chemicals
    Industrials

    SEC Form 4 filed by Interim CFO De Notaris Mike

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/10/25 4:30:52 PM ET
    $LOOP
    Major Chemicals
    Industrials

    New insider De Notaris Mike claimed ownership of 20,828 shares (SEC Form 3)

    3 - Loop Industries, Inc. (0001504678) (Issuer)

    11/10/25 4:30:24 PM ET
    $LOOP
    Major Chemicals
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Leadership Updates

    Live Leadership Updates

    View All

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

    Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

    3/25/25 8:46:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    11/14/24 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

    SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 6:16:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:12:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Financials

    Live finance-specific insights

    View All

    Gulf Island Reports Third Quarter 2025 Results

    THE WOODLANDS, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Gulf Island Fabrication, Inc. (NASDAQ:GIFI) ("Gulf Island" or the "Company"), a leading steel fabricator and service provider to the industrial, energy and government sectors, today announced its results for the third quarter 2025. THIRD QUARTER 2025 SUMMARY Consolidated revenue of $51.5 millionConsolidated net income of $1.6 million; Consolidated adjusted EBITDA of $2.5 millionServices division operating income of $0.8 million; EBITDA of $1.3 millionFabrication division operating income of $2.1 million; EBITDA of $2.9 millionFabrication division awarded large structural steel components contract to support the rebuild of the Franc

    11/12/25 4:05:00 PM ET
    $GIFI
    Metal Fabrications
    Industrials

    IES Holdings to Acquire Gulf Island Fabrication

    HOUSTON and THE WOODLANDS, Texas, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IES Holdings, Inc. ("IES") (NASDAQ:IESC) and Gulf Island Fabrication, Inc. ("Gulf Island") (NASDAQ:GIFI) today announced that they have entered into a definitive agreement, providing for the acquisition of Gulf Island, a leading steel fabricator and service provider to the industrial, energy and government sectors, by IES. Under the terms of the agreement, IES will pay $12.00 in cash per Gulf Island share, or an aggregate equity value of approximately $192 million. The transaction has been approved by the boards of directors of both companies and is currently expected to close in the quarter ending March 31, 2026, subject

    11/7/25 8:15:00 AM ET
    $GIFI
    $IESC
    Metal Fabrications
    Industrials
    Engineering & Construction

    FGI INDUSTRIES ANNOUNCES SECOND QUARTER 2025 RESULTS

    EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results for the second quarter 2025. SECOND QUARTER 2025 HIGHLIGHTS(As compared to the second quarter of 2024) Total revenue of $31.0 million, +5.5% y/yGross profit of $8.7 million, -2.9% y/yGross margin of 28.1%, -240 bps y/yOperating loss of $0.8 million and net loss attributable to shareholders of $1.2 millionAdjusted operating loss of $0.8 millionAdjusted net loss of $1.2 millionMANAGEMENT COMME

    8/11/25 4:15:00 PM ET
    $FGI
    Industrial Specialties
    Industrials